Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 3/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1808081 | 1.00 | TGFBR1 (0.42) | TGFBR1JAK3BTKMMEFAAH | |
| SCHEMBL838395 | 0.85 | JAK3 (0.35) | TGFBR1JAK3BTKFAAH | |
| SCHEMBL14796619 | 0.85 | JAK3 (0.35) | TGFBR1JAK3BTKFAAH | |
| SCHEMBL16164638 | 0.84 | CA12 (0.35) | TGFBR1JAK3BTKFAAH | |
| SCHEMBL22478842 | 0.83 | TGFBR1 (0.35) | TGFBR1JAK3BTKFAAH | |
| SCHEMBL329020 | 0.82 | JAK3 (0.39) | TGFBR1JAK3BTKMMEFAAH | |
| SCHEMBL17629514 | 0.82 | ALDH1A1 (0.42) | MMEFAAH | |
| SCHEMBL4783334 | 0.82 | JAK3 (0.39) | TGFBR1JAK3BTKMMEFAAH | |
| SCHEMBL25360136 | 0.81 | JAK3 (0.38) | TGFBR1JAK3BTKFAAH | |
| SCHEMBL25360128 | 0.81 | JAK3 (0.38) | TGFBR1JAK3BTKFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358951-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-3402777-B1 | OXAZOLIDINONES AS TARO INHIBITORS | MERCK SHARP & DOHME (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11738010-B2 | Oxazolidinones as TarO inhibitors | MERCK SHARP & DOHME CORP. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230093692-A1 | C10-Alkylene Substituted 13-Membered Macrolides and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-11279735-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20210346364-A1 | OXAZOLIDINONES AS TARO INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-11-11 | — | — | US | disclosed |
| US-11141410-B2 | Oxazolidinones as taro inhibitors | MERCK SHARP & DOHME CORP (US) | 2021-10-12 | — | — | US | disclosed |
| EP-3883647-A1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | Zikani Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200261436-A1 | OXAZOLIDINONES AS TARO INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
| EP-3402777-A1 | OXAZOLIDINONES AS TARO INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-11-21 | — | — | EP | disclosed |
| WO-2017106138-A1 | OXAZOLIDINONES AS TARO INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | TGFBR1 3584/4885JAK3 3792/4885BTK 1440/4885 |
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | TGFBR1 3584/4885JAK3 3792/4885BTK 1440/4885 |
| US-20210346364-A1 | OXAZOLIDINONES AS TARO INHIBITORS | OXA1L, DDO, ALPI | TGFBR1 2111/4885JAK3 3512/4885BTK 1283/4885 |
| US-12358951-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | TGFBR1 3584/4885JAK3 3792/4885BTK 1440/4885 |
| US-20200261436-A1 | OXAZOLIDINONES AS TARO INHIBITORS | OXA1L, DDO, ALPI | TGFBR1 2111/4885JAK3 3512/4885BTK 1283/4885 |
| US-11279735-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | TGFBR1 3584/4885JAK3 3792/4885BTK 1440/4885 |
| US-11141410-B2 | Oxazolidinones as taro inhibitors | OXA1L, DDO, ALPI | TGFBR1 2111/4885JAK3 3512/4885BTK 1283/4885 |
| US-20230093692-A1 | C10-Alkylene Substituted 13-Membered Macrolides and Uses Thereof | RPS14, RPL17, RPN2 | TGFBR1 4769/4885JAK3 2137/4885BTK 1731/4885 |
| US-11738010-B2 | Oxazolidinones as TarO inhibitors | OXA1L, DDO, ALPI | TGFBR1 2111/4885JAK3 3512/4885BTK 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.